Amgen submits applications in U.S. and Europe for Kyprolis® (carfilzomib)
Amgen and its subsidiary Onyx Pharmaceuticals announced submission of a sNDA to the FDA and a MAA to the EMA for Kyprolis® (carfilzomib) for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. January 27, 2015